Sector
PharmaceuticalsOpen
₹2.71Prev. Close
₹2.85Turnover(Lac.)
₹0.04Day's High
₹2.95Day's Low
₹2.7152 Week's High
₹5.1152 Week's Low
₹2.51Book Value
₹-55.78Face Value
₹10Mkt Cap (₹ Cr.)
6.46P/E
0EPS
0Divi. Yield
012 Aug 2024
12:00 AM
Board Meeting
Agenda : Audited Result
9 Sep 2023
12:00 AM
AGM
Announcement Date: 09 Sep, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 23.83 | 23.83 | 23.83 | 23.83 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -151.81 | -146.25 | -131.03 | -111.8 |
Net Worth | -127.98 | -122.42 | -107.2 | -87.97 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | -100 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -1.39 | -1.79 | -2.42 | -3.11 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -19.23 | -21 | -23.92 | -19.23 |
Depreciation | -5.63 | -5.87 | -6.44 | -6.78 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | -3.83 | -4.65 | -3.11 | 7.09 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | -100 |
Op profit growth | 305.58 | -77.23 | -25.31 | -184.17 |
EBIT growth | 28.46 | -30.7 | 95.07 | 131.74 |
Net profit growth | -8.44 | -12.19 | 24.35 | 16.88 |
| Particulars (Rupees in Crores.) | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Gross Sales | 103.19 | 403.66 | 287.26 | 162.12 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 103.19 | 403.66 | 287.26 | 162.12 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 0.25 | 0.37 | 0.23 | 0.25 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Ajit Kamath
Non-Exec & Non-Independent Dir
Rajendra Kaimal
Company Sec. & Compli. Officer
Jignesh Patel
Non-Exec. & Independent Dir.
Sunil Pitroda
Non-Exec. & Independent Dir.
Abhishek Buddhadev
Non-Exec. & Independent Dir.
Urja Shah
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Kobo Biotech Ltd
Summary
Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992. Effective 19th October, 2020, the Companys name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited. The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The companys 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US. XTP shall be the technical supervisor for the transfer of technology, while SMEC shall supply the technical knowhow.The company has bagged the award for the Best New Product manufactured in the State of Andhra Pradesh as awarded by the Federation of Andhra Pradesh Chamber of Commerce and Industry and also certified as an ISO 9002 company by American Quality Asseassors accredited with ANSI-RAB for the manufacturing and marketing MMAA, MMAE, DEA, EEAA and Aralydes.The company had developed technology for recovery of Diketene from sludge. The company has also diversified into Bio-Techno
Read More
What is the Kobo Biotech Ltd share price today?
The Kobo Biotech Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹2.71 today.
What is the Market Cap of Kobo Biotech Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kobo Biotech Ltd is ₹6.46 Cr. as of 09 May ‘25
What is the PE and PB ratio of Kobo Biotech Ltd?
The PE and PB ratios of Kobo Biotech Ltd is 0 and -0.05 as of 09 May ‘25
What is the 52 Week High and Low of Kobo Biotech Ltd?
The 52-week high/low is the highest and lowest price at which a Kobo Biotech Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kobo Biotech Ltd is ₹2.51 and ₹5.11 as of 09 May ‘25
What is the CAGR of Kobo Biotech Ltd?
Kobo Biotech Ltd's CAGR for 5 Years at 6.40%, 3 Years at -20.63%, 1 Year at -29.46%, 6 Month at -3.06%, 3 Month at -4.36% and 1 Month at -0.70%.
What is the shareholding pattern of Kobo Biotech Ltd?
The shareholding pattern of Kobo Biotech Ltd is as follows:
Promoters - 44.95 %
Institutions - 0.66 %
Public - 54.39 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
